Skip to main content Skip to main navigation menu Skip to site footer

The correlation between serum matrix metalloproteinase-9 levels and the severity of coronary artery stenosis in patients with acute coronary syndrome

  • Rico Rasaki ,
  • Teuku Heriansyah ,
  • Muhammad Ridwan ,
  • Novita ,
  • Haris Munirwan ,

Abstract

Link of Video Abstract: https://www.youtube.com/watch?v=mzVt00Yaibk

Introduction
: Atherosclerosis causes coronary artery stenosis in a lot of patients with acute coronary syndrome (ACS). By controlling platelet activity and destroying the extracellular matrix, a group of enzymes known as matrix metalloproteinases (MMPs) contribute to the plaque rupture process that causes ACS. The study aimed to determine whether there was any correlation between the amount of serum MMP-9 and the severity of coronary artery stenosis in ACS patients.

Methods: Cross-sectional analytical observational design was employed in this investigation. The research population consisted of ACS patients at the Dr. Zainoel Abidin General Hospital in Banda Aceh, Indonesia. Patients who were included as samples had to satisfy the inclusion and exclusion requirements. This study used analysis of variance (ANOVA) as a bivariate analysis to examine the connection between blood MMP-9 levels and the severity of coronary artery stenosis. The threshold for statistical significance was a p-value≤0.05.

Results: This research comprised 40 patients with ACS, of which 14 had STEMI, 11 had NSTEMI, and 15 had unstable angina pectoris (UAP). Eleven individuals had mild coronary artery stenosis, eleven had moderate stenosis, and eighteen had severe stenosis, according to an analysis of the Gensini score. Bivariate analysis revealed no significant relationship between blood MMP-9 levels and the degree of coronary artery stenosis in ACS patients (p-value = 0.434).

Conclusions: In patients with ACS at the Dr. Zainoel Abidin General Hospital in Banda Aceh, Indonesia, there was no statistically significant association between serum MMP-9 levels and the degree of coronary artery stenosis, according to this study.

References

  1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-16823. doi:10.1002/jcp.28350.
  2. Voudris KV, Kavinsky CJ. Advances in Management of Stable Coronary Artery Disease: The Role of Revascularization? Curr Treat Options Cardiovasc Med. 2019;21(3):15. doi:10.1007/s11936-019-0720-9.
  3. Sayols-Baixeras S, Lluís-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014;7:15-32. doi:10.2147/TACG.S35301.
  4. Hamed GM, Fattah MF. Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost. 2015;21(8):705-11. doi:10.1177/1076029614567309.
  5. Andreou I, Antoniadis AP, Shishido K, Papafaklis MI, Koskinas KC, et al. How do we prevent the vulnerable atherosclerotic plaque from rupturing? Insights from in vivo assessments of plaque, vascular remodeling, and local endothelial shear stress. J Cardiovasc Pharmacol Ther. 2015;20(3):261-75. doi:10.1177/1074248414555005.
  6. Hassanzadeh-Makoui R, Razi B, Aslani S, Imani D, Tabaee SS. The association between Matriks Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis. BMC Cardiovasc Disord. 2020 May 19;20(1):232. doi: 10.1186/s12872-020-01510-4. PMID: 32429880; PMCID: PMC7236475.
  7. Dabek J, Kulach A, Gasior Z. The role of matrix metalloproteinases in acute coronary syndromes. Eur J Intern Med. 2007;18(6):463-6. doi: 10.1016/j.ejim.2007.01.007.
  8. Shu J, Ren N, Du JB, Zhang M, Cong HL, et al. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand Cardiovasc J. 2007 Jun;41(3):149-54. doi: 10.1080/14017430601164263.
  9. de Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):340-6. doi: 10.1161/01.ATV.0000197795.56960.64.
  10. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005 Jan;85(1):1-31. doi: 10.1152/physrev.00048.2003
  11. Kalela A, Koivu TA, Sisto T, Kanervisto J, Höyhtyä M, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest. 2002;62(5):337-42. doi:10.1080/00365510260296483.
  12. Nishiguchi T, Tanaka A, Taruya A, Emori H, Ozaki Y, et al. Local Matrix Metalloproteinase 9 Level Determines Early Clinical Presentation of ST-Segment-Elevation Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2016;36(12):2460-2467. doi:10.1161/ATVBAHA.116.308099.

How to Cite

Rasaki, R., Heriansyah, T., Ridwan, M., Novita, & Munirwan, H. (2023). The correlation between serum matrix metalloproteinase-9 levels and the severity of coronary artery stenosis in patients with acute coronary syndrome. Bali Medical Journal, 12(2), 2196–2199. https://doi.org/10.15562/bmj.v12i2.4583

HTML
19

Total
14

Share